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 Sound symbolism provides a useful framework when developing pharmaceutical brand 
name 
 Voiced (vs. voiceless) consonants in brand names increase expected efficacy of medicine   
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ABSTRACT 
Given the worldwide growth of the over-the-counter (OTC) drug market and the 
increase in the direct-to-consumer advertising of medicines, pharmaceutical branding has 
become an increasingly important component affecting the consumer’s beliefs about, and 
hence their responses towards, OTC medicines. The brand name is one of the most important 
external cues for brand evaluation and influences various aspects of consumer-brand 
association (e.g., perceived quality/efficacy, brand attitude, and brand image). Although sound 
symbolism, which refers to the non-arbitrary association that exists between particular sound 
sequences and specific meanings in speech, has proven to be an effective means of creating 
successful brand names in a wide range of products, surprisingly little attention has been paid 
to its application in the case of pharmaceutical branding. In this study, we systematically 
investigated whether and how consonants in drug brand names influence consumers’ medicine 
expectancies (e.g., medicinal power, long-lasting efficacy). Across three experiments, a robust 
effect of voiced (vs. voiceless) consonants present in brand names on the perceived potency 
and activity for target medicines was found. In addition, the results also revealed that voiced 
(vs. voiceless) consonants increase the expectancies of medicine effectiveness, duration of 
medicine activity, price, and potential side effects. Furthermore, we found that the perceived 
potency and activity for brand names significantly mediated the effect of voiced consonants. 
Taken together, these findings enhance our understanding of the role of consonant sound 
symbolism in brand name development and can potentially help pharmaceutical firms to create 
appropriate brand names that can effectively communicate information concerning a 
medicine’s properties. 
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1. Introduction  
Imagine a consumer who suffers from severe hay fever inspecting a couple of over-the-
counter (OTC) anti-allergy drugs, one named “Sanasas” and the other “Danadas”. Which one 
would likely appeal more to the consumer, all other things being equal? According to the results 
of the research reported here, they would probably prefer “Danadas”, as the speech sounds 
present in the brand name are more potent and active, thereby conveying an impression of a 
more powerful and longer-lasting medicine. 
With the rapid growth in direct-to-consumer advertising in the pharmaceutical industry, 
branding and marketing have become increasingly important elements in terms of setting the 
right expectations in the mind of the consumer. In 2018, the global OTC drug market exceeded 
USD 125 bn. and is forecast to grow to USD 185 bn. by the year 2025 (Global Market Insight, 
2019). With the competition intensifying, more and more companies are offering their drugs 
as OTC products in retail outlets, supermarkets, and even online stores. Like many other 
packaged food and beverage products, the consumer’s perception of OTC drugs is influenced 
by a variety of external cues such as advertising, packaging, and even the brand name. 
Although published research on pharmaceutical branding is still in its infancy, there is 
plenty of evidence to suggest that various extrinsic cues such as packaging (e.g., Kauppinen-
Räisänen, 2010; Roulette & Droulers, 2005), brand name (e.g., Dohle & Siegrist, 2014; McNeil, 
2003), and pill color and shape (e.g., Bakalar, 2012; Wan, Woods, Velasco, Salgado-Montejo, 
& Spence, 2015) can all influence a consumer’s product expectations and perception. For 
example, Roulette and Droulers (2005) demonstrated that the use of dark colors in 
pharmaceutical packaging helps to convey the impression of higher potency. Meanwhile, 
Dohle and Siegrist (2014) demonstrated that the processing fluency of drug names (e.g., hard-
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well as their willingness-to-pay (WTP) for the product. More relevant specifically to the current 
research, Abel and Glinert (2008) indicated that the brand names of commercial chemotherapy 
drugs contain more voiceless consonants (e.g., [p], [s]; thought to be associated with fastness 
and lightness) than voiced consonants (e.g., [b], [z]; thought to be associated with slowness and 
heaviness). Through the survey, they speculated that as the treatment of chemotherapy is 
accompanied in many patients by a strong sense of trepidation, hence the sounds of 
chemotherapy names that are associated with lightness, smallness, and fastness may help to 
mitigate concerns about side effects and/or result in better treatment experiences. The current 
research focuses on the product expectations that are associated with specific brand names. In 
particular, we investigated the influence of sounds contained in a pharmaceutical brand name 
(i.e., sound symbolism) on the consumers’ expectations concerning the product’s qualities and 
efficacy.  
The brand name is widely recognized as one of the most important external cues for 
brand evaluation including perceived quality (Dawar & Parker, 1994; Klink, 2000; Kohli & 
LaBahn, 1997; Wänke, Herrmann, & Schaffner, 2007), brand attitude (Klink, 2001, 2003; 
Zinkhan & Martin, 1987), and brand image (Del Río, Vázquez, & Iglesias 2001; Pavia & Costa, 
1993). The effective use of sound symbolism has been shown to provide an effective means of 
creating successful brand names across a wide-range of products (Klink, 2001; Spence, 2012). 
However, with few exceptions (e.g., Abel & Glinert, 2008), surprisingly little attention has 
been paid to the application of the sound symbolic framework to the development of 
pharmaceutical brand names. The current research aims to bridge this gap and investigate the 
effect of the presence (vs. absence) of certain consonants in pharmaceutical brand names on 
the expectations of consumers. 
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Sound symbolism refers to the non-arbitrary mappings that exist between phonetic 
properties of speech sounds and their meanings (e.g., Knoferle, Li, Maggioni, & Spence, 2017; 
Sidhu & Pexman, 2018). The effect of incorporating sound symbolic features in brand names 
on the perception of consumers has been demonstrated across a wide range of product 
categories from durable goods (e.g., cars, laptops), daily goods (e.g., toilet paper, toilet cleaner), 
and fashion items (e.g., dresses, cologne) through to foods and beverages (e.g., ice cream, beer, 
and chocolate; e.g., Arroyo & Arboleda, 2020; Klink, 2000; Klink & Wu, 2014; Lowrey & 
Shrum, 2007; Pathak, Calvert, & Lim, 2020; Pathak, Calvert, & Motoki, 2020; Spence, 2014; 
Yorkston & Menon, 2004). 
A considerable body of research links the vowels present in the brand names with 
specific product attributes. For example, front vowels (e.g., the sound of [i], [e]) are perceived 
as smaller, lighter, brighter, more feminine and less creamy (Klink, 2000; Yorkston & Menon, 
2004), whereas back vowels (e.g., the sound of [o], [u]) are perceived as larger, heavier, darker, 
creamier and more masculine (e.g., Lowrey & Shrum, 2007; Klink, 2000; Klink & Athaide, 
2012; Yorkston & Menon, 2004). 
Compared to vowels, less attention has so far been paid to the role of consonant sounds 
in sound symbolism and brand name development (Guèvremont & Grohmann, 2015). 
Consonants can be categorized into voiceless or voiced in terms of the type of voicing (Klink, 
2000; Sidhu & Pexman, 2018). A voiceless consonant is produced without any vibration of the 
vocal cords (e.g., [f], [s], [p], [t]), whereas a voiced consonant is made with the accompanying 
vibrations of the vocal cords (e.g., [v], [z], [b], [d]). Voiceless/voiced consonants can be further 
subdivided into fricatives and stops (Sidhu & Pexman, 2018). A fricative consonant is produced 
by squeezing air between a small gap as it leaves the mouth and has less closure of the 
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complete closure of the articulators so that all airflow ceases in the mouth. Sounds such as [f], 
[s], and [v], [z] are voiceless and voiced fricatives, respectively. Meanwhile, sounds such as 
[p], [t], and [b], [d] are considered as voiceless and voiced stops, respectively. Although 
research on the topic of sound symbolism associated with consonants is relatively sparse, a few 
studies have examined the frequency of consonants appearing in famous brand names (Pathak, 
Velasco, & Spence, 2020; Van Doorn, Paton, & Spence, 2016) as well as the influence of 
consonant sounds in brand names on the response of consumers (Guevrèmont & Grohmann, 
2015; Motoki et al., 2020; Pathak, Calvert, & Lim, 2020). For instance, Pathak et al. (2020) 
found that consumers perceive products (e.g., beer, toilet cleaner) with brand names that 
include voiced (vs. voiceless) consonants as having stronger and hasher product attributes (e.g., 
strong beer).  
 1.2. Voiced consonants and pharmaceutical branding 
 Osgood’s three dimensions of connotative meaning (i.e., evaluation, potency, and 
activity) were used to examine the influence of consonant sounds in brand names on consumer 
impressions of medicines (Osgood, Suci, & Tannenbaum, 1957; Tannenbaum, Jacobson, & 
Norris, 1964). The evaluation dimension can be measured with bipolar items such as “nice–
awful”, and “good–bad”. Meanwhile, the dimensions of potency and activity are typically 
assessed using items such as “powerless–powerful”, “weak–strong” and “slow–fast”, 
“passive–active”, respectively. Osgood’s three dimensions of connotative meaning have been 
applied in a variety of contexts such as color (Valdez & Mehrabian, 1994), angularity (Velasco, 
Woods, Marks, Cheok, & Spence, 2016), typeface (Doyle & Bottomley, 2006), and packaging 
(Roullet & Droulers, 2005). Specifically, Sidhu and Pexman (2018) suggested that the effects 
of sound symbolism emerge due to the connotative meanings inherent to the sounds (e.g., 
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dimension related to shape). Thus, it would seem reasonable to expect the effect of sound 
symbolism in pharmaceutical branding due to the connotative meanings of these sounds. 
Research in sound symbolism suggests that voiced (vs. voiceless) consonants are linked 
to impressions related to potency (e.g., strong, powerful). Since words or names with voiced 
(vs. voiceless) consonants are perceived to be larger, heavier, stronger, and more masculine 
(Pathak et al., 2020; Shih, Ackerman, Hermalin, Inkelas, & Kavitskaya, 2018; Slepian & 
Galinsky, 2016), we expected that the perceived potency of medicines would be higher (vs. 
lower) when the brand names contain voiced (vs. voiceless) consonants. 
Compared to potency, it is rather difficult to predict the effect of voicing on the 
perception of the activity dimension (e.g., fast, active). Since voiceless consonants are more 
closely associated with fastness than voiced consonants (e.g., Abel & Glinert, 2008; Klink, 
2000), voiced (vs. voiceless) consonants in brand names can decrease the perception of activity. 
At the same time, however, it should be noted that the potency and activity dimensions are not 
perfectly orthogonal and may integrate into the dimension of “dynamism” (Kervyn, Fiske, & 
Yzerbyt, 2013; Osgood et al., 1957). Given that the potency and activity dimensions are 
positively related, we expected that, as with the potency dimension, voiced (vs. voiceless) 
brand names might increase the perceived activity of the medicines. 
Voiced (vs. voiceless) sounds are associated more with negative concepts such as 
dirtiness and ugliness and perceived as less pleasing (Fjeldsted, 1991; Motoki et al. 2020; 
Pathak et al., 2020). For instance, Motoki et al. (2020) reported that foods are perceived more 
favorably when those names contain voiceless consonants rather than voiced ones. Thus, it was 
expected that the perceived evaluation for medicines will be lower when the brand names 



































































RUNNING HEAD: DRUG NAMES AND THE EXPECTED EFFICACY OF MEDICINES  
2. Experiment 1 
The purpose of Experiment 1 was to examine the effect of voiced sounds present in 
brand names on the ratings of medicine using Osgood’s semantic differential scale. Specifically, 
we examined whether voiced (vs. voiceless) consonants would influence the rated EPA 
dimensions (evaluation, potency, and activity) of a hypothetical new anti-allergy medicine.1 
2.1. Method 
2.1.1. Design and participants 
  The experiment was a 2 (type of voicing: voiceless, voiced) × 2 (manner of articulation: 
fricative, stop) between-participants design. The dependent variable was ratings of twelve 
seven-point bipolar Osgood’s EPA measurements (Osgood, 1964; Osgood et al., 1957) adapted 
from Velasco et al. (2016). 
  The participants in all three of the experiments were recruited online from Yahoo Crowd 
Sourcing service (https://crowdsourcing.yahoo.co.jp/) provided by Yahoo! Japan Corporation 
and completed the questionnaire on Survey Monkey (https://www.surveymonkey.com/). All 
three of the experiments that are reported here were conducted in accordance with the ethical 
guidelines of the first author’s university and the Declaration of Helsinki. Two hundred and 
twenty-eight respondents participated in Experiment 1 (77 females, mean age of 46.9 years, 
SD = 10.4)2 and received a point worth 20 JPY as compensation. 
                                               
1  Anti-allergy medicine (Experiment 1), painkiller (Experiment 2), and stomach relief 
(Experiment 3) were chosen as target medicines as these are easily available OTC drugs that 
most consumers are likely to be at least somewhat familiar with. 
2 A priori power analyses using G*power 3.1 (Faul, Erdfelder, Lang, & Buchner, 2007) for all 
experimental designs indicated that the number of recruited participants in each study was 
sufficient to detect a medium effect size (f = 0.25) with 95% power at an alpha level of .05 as 
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2.1.2. Stimuli 
 Four fictitious brand names were created using a voiceless and voiced fricative (i.e., [f], 
[v]) and a voiceless and voiced stop (i.e., [p], [b]), while controlling for other sounds in the 
names: FANTEC, VANTEC, PANTEC, and BANTEC. 
2.1.3. Procedure 
At the start of the experiment, the participants were welcomed and it was explained that 
the study concerned an OTC medicine. After providing their consent, the participants were 
randomly assigned to one of four brand name conditions. First, they were informed that a 
pharmaceutical company had developed an anti-allergy medicine named “______ (indicated 
one of FANTEC, VANTEC, PANTEC, or BANTEC)”. Subsequently, participants rated the 
medicine on twelve seven-point bipolar semantic differential EPA items across three 
dimensions, 1) evaluation; including nice–awful, good–bad, mild–harsh, and happy–sad (α 
= .87), 2) potency; including powerless–powerful, weak–strong, light–heavy, and shallow–
deep (α = .79) and, 3) activity; including slow–fast, quiet–noisy, passive–active, and dead–
alive (α = .72). At the end of the study, the participants reported their gender and age. 
2.2. Results  
Three two-way analyses of variance (ANOVAs) were conducted for the EPA 
dimensions (see Figure 1). The results of the analysis of the evaluation dimension indicated a 
significant main effect of the type of voicing (voiceless vs. voiced), (F(1, 224) = 6.51, p = .011, 
ηp
2 = .028). However, contrary to our predictions, the perceived evaluation of the medicine was 
higher in the voiced (vs. voiceless) name condition (Mvoiced = 4.39, SD = 0.85; Mvoiceless = 4.14, 
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significant (F(1, 224) = 1.58, p = .21, ηp
2 = .01), nor was there any interaction between the type 
of voicing and the manner of articulation either (F(1, 224) = 3.08, p = .08, ηp
2 = .01). 
The results of the ANOVA regarding potency revealed a significant main effect of the 
type of voicing (F(1, 224) = 12.15, p < .001, ηp
2 = .05). As expected, brand names incorporating 
voiced (vs. voiceless) consonants induced higher perceived activity for the medicine (Mvoiced = 
4.49, SD = 0.78; Mvoiceless = 4.15, SD = 0.71). On the other hand, neither the main effect of the 
manner of articulation, nor the interaction between the type of voicing and the manner of 
articulation, were significant (all Fs < 1.56, ps > .21). 
The results of the activity dimension highlighted significant main effect of the type of 
voicing (F(1, 224) = 12.78, p < .001, ηp
2 = .05). Voiced (vs. voiceless) brand names, as expected, 
resulted in higher perceived activity for the medicine (Mvoiced = 4.43, SD = 0.78; Mvoiceless = 
4.11, SD = 0.63). Meanwhile, no significant main effect of the manner of articulation nor any 
interaction between the type of voicing and the manner of articulation were found (all Fs < 
1.58, ps > .11).  
 
Fig. 1. Results of perceived evaluation, potency, and activity of the medicine in Experiment 1. 
Note: Error bars indicate standard errors of mean. Asterisks indicate post-hoc significant 
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2.3. Discussion 
 The results of Experiment 1 revealed that brand names containing voiced (vs. voiceless) 
consonants increased the rated evaluation, potency, and activity of a hypothetical new anti-
allergy medicine. Meanwhile, the presence of stop (vs. fricative) consonants in the brand names 
did not influence ratings for any of the dimensions. Additionally, no significant interaction 
between voiced and stop consonants was documented for any of the three dimensions. 
3. Experiment 2 
  Experiment 2 was designed to examine the effect of voiced consonants in brand names 
on consumers' EPA ratings of a medicine in a more realistic setting. To do this, we tested the 
effect of voiced sounds on consumer responses to a medicine using brand packaging for a 
painkiller. 
3.1. Method 
3.1.1. Design and participants 
  The experimental design was a 2 (type of voicing: voiceless, voiced) × 2 (manner of 
articulation: fricative, stop) between-participants design. The dependent variable was the same 
ratings of EPA dimensions as used in Experiment 1.  
  Two hundred and nineteen respondents took part in Experiment 2 (94 females, mean age 
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Four versions of fictitious painkiller packages were created with brand names that 
included one of four consonants (i.e., [f], [v], [p], [b]) used in Experiment 1 (see Table 1). 
Table 1. The package stimuli used in Experiment 2.  
 
3.1.3. Procedure  
The procedure was similar to that used in Experiment 1, except that instead of text 
stimuli, participants were shown color images of product packages. First, they were presented 
with the image of the packaging of drugs and it was explained that the product was a painkiller 
that had been recently developed by a pharmaceutical company. Subsequently, the participants 
rated the painkiller on the same 12 bipolar EPA items used in Experiment 1 (evaluation, α 
= .81; potency, α = .90; activity, α = .77). 
3.2. Results 
Three two-way ANOVAs were performed for each of the EPA dimensions (see Figure 
2). The results of the evaluation dimension indicated no significant main effects of voicing type 
(F(1, 215) = 1.786, p = .18, ηp
2 = .01) or manner of articulation (F < 1, p = .51), nor any 
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The results of the potency dimension revealed a significant main effect of the type of 
voicing (F(1, 215) = 9.62, p = .002, ηp
2 = .043). Consistent with the results of Experiment 1, 
those drugs with voiced (vs. voiceless) brand names resulted in higher perceived potency for 
the medicine (Mvoiced = 4.26, SD = 0.95; Mvoiceless = 3.85, SD = 0.95). On the other hand, there 
was no main effect of the manner of articulation, nor any interaction between the type of 
voicing and the manner of articulation (all Fs <1, ps > .42). Regarding the activity dimension, 
the results revealed a significant main effect of the type of voicing (F(1, 215) = 4.42, p < .001, 
ηp
2 = .02). As expected, and consistent with the results of Experiment 1, the perceived activity 
of the medicine was higher in the voiced (M = 4.10, SD = 0.82) than in the voiceless name 
condition (M = 3.87, SD = 0.84). Meanwhile, neither a significant main effect of the manner of 
articulation nor a significant interaction between the type of voicing and the manner of 
articulation was found (all Fs < 1.08, ps > .31). 
 
 
Fig. 2. Results of Experiment 2. Note: Error bars indicate standard errors. Asterisks indicate 
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The results of Experiment 2 replicated the findings of Experiment 1 and demonstrated 
that brand names with voiced (vs. voiceless) consonants are perceived as having higher potency 
and activity for a packaged painkiller. However, inconsistent with the results of Experiment 1, 
the type of voicing did not influence ratings of the perceived evaluation of the medicine. 
Meanwhile, as with Experiment 1, stop (vs. fricative) consonants in the brand names did not 
affect the ratings of the various EPA dimensions. No significant interactions between voiced 
consonants and stops were observed for any of the three dimensions. 
4. Experiment 3 
Experiment 3 was designed to examine the effect of the voiced consonants present in 
brand names on the expected properties of medicines and the underlying mechanisms behind 
the effect. Specifically, we investigated whether, and how, the rated EPA for the brand names 
mediated the influence of voiced sounds in brand names on the expectations of consumers. 
To measure the expectations that people have with hypothetical new medicines, we 
partially used the drug expectancy measurements of Roullet and Droulers (2005), consisting of 
the expectations of medicine effectiveness, duration of drug activity, price, and potential side 
effects. Voiced (vs. voiceless) consonants are, as stated above, perceived to be heavier, stronger, 
and more masculine. Thus, we predicted that they would be perceived as having a greater 
medicinal effectiveness, longer-lasting effectiveness, and also possibly more potential side 
effects. The concept of heaviness (vs. lightness) is metaphorically linked to higher perception 
of value (Ackerman, Nocera, & Bargh, 2010; Piqueras-Fiszman & Spence, 2012; Zhang & Li, 
2012). Thus, it was expected that medicine with brand names containing voiced (vs. voiceless) 
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To examine the effect of consonant sound in brand names more broadly, in addition to 
the labial consonants (i.e., [f], [v], [p], [b]) used in Experiments 1 and 2, coronal consonants 
(i.e., [s], [z], [t], [d]) were also used in Experiment 3. While a labial sound is produced with the 
lips, the sound of a coronal consonant is produced with the tongue. A number of studies have 
shown that labial consonants are associated with ‘baby-ness’ and consequently are associated 
with smallness (Kumagami & Kawahara, 2018; Shih, Ackerman, Hermalin, Inkelas, & 
Kavitskaya, 2018). These studies suggest that coronal consonants may associate more with size 
as compared to labials. Thus, we expected the effect of voiced brand names on medicine 
expectancies to be more prominent in coronal consonant conditions than in labial ones. 
4.1. Method 
4.1.1. Design and participants 
  The experimental design was a 2 (type of voicing: voiceless, voiced) × 2 (manner of 
articulation: fricative, stop) × 2 (place of pronunciation: labial, coronal) between-participants. 
The dependent variable was the same ratings of the EPA dimensions used in Experiments 1 
and 2. Six hundred and nineteen-five respondents participated in Experiment 3 (366 females, 
mean age of 45.1 years, SD = 9.6). They received a point worth 25 JPY as compensation in 
return for completing the survey. 
4.1.2. Stimuli 
Eight versions of fictitious stomach relief packages were created with brand names 
using the above mentioned four labial consonants ([f], [p], [v], [b]) and four coronal consonants 
([s], [t], [z], [d]) (see Table 2). The package design is identical to that used in Experiment 1 but 
to avoid the possible confounding effects of color, we used grayscale images. The eight brand 
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Table 2. The package stimuli used in Experiment 3.  
 
4.1.3. Procedure  
The participants were randomly assigned to one of the eight package conditions. First, 
they were presented with a grayscale image of the drug package and it was explained that the 
drug was designed to provide relief for stomach pain and heartburn that had been recently 
developed by an unnamed pharmaceutical company. Subsequently, participants rated their 
impression of the brand name on the same 12 bipolar EPA items used in Experiments 1 and 2 
(evaluation, α = .76; potency, α = .88; activity, α = .75). Next, they rated the drug expectancies 
on five 7-point bipolar scales adapted from the work of Roullet and Droulers (2005). These 
items comprised: medicine effectiveness (weak-strong), duration of drug activity (short-long), 
price (cheap-expensive), and potential side effects (low-high). 
 4.2. Results 
4.2.1. The effect of voicing on medicine expectancies 
To examine the effect of voiced consonants in brand names on the evaluation of 
consumers’ expectations concerning the properties of the medicine, four three-way ANOVAs 
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as independent variables and the items of the drug expectancies as dependent variables (see 
Appendix Table A for the mean ratings of all eight brand names).  
4.2.1.1. Medicine effectiveness 
 The analysis regarding the expectation of medicine effectiveness revealed a significant 
main effect of the type of voicing (F(1, 687) = 25.94, p < .001, ηp
2 = .04): specifically, the 
drugs with voiced (vs. voiceless) brand names were perceived as being more effective (Mvoiced 
= 4.47, SD = 1.26; Mvoiceless = 4.02, SD = 1.22). On the other hand, the main effects of the 
manner of articulation (F < 1, p = .35), and the place of pronunciation (F(1, 687) = 2.46, p 
= .20, ηp
2 = .00), were not significant. There was a significant interaction between the type of 
voicing and the place of pronunciation (F(1, 687) = 4.90, p = .027, ηp
2 = .01): the effect of 
voiced (vs. voiceless) consonants in brand names on the expectations of our participants was 
greater when the names contained coronal consonants (F(1, 687) = 26.28, p < .001, ηp
2 = .04) 
than labial ones (F(1, 687) = 4.22, p = .04, ηp
2 = .01). The interactions between the type of 
voicing and the manner of articulation (F < 1, p = .60) and between the manner of articulation 
and the place of pronunciation (F(1, 687) = 3.75, p = .053, ηp
2 = .01) were not significant. The 
interaction term was qualified by a significant three-way interaction between the type of 
voicing, manner of articulation, and the place of pronunciation (F(1, 687) = 4.16, p = .042, ηp
2 
= .01; see Figure 3). When the data were split into stop and fricative consonants, different 
interactions were observed. When the names included stop consonants, no significant 
interaction was found between the type of voicing and the place of pronunciation (F < 1, p 
= .90): voiced (vs. voiceless) consonants increased the perceived medicine power both in labial 
and coronal brand name groups (labials: F(1, 347) = 6.63, p = .01, ηp
2 = .02; coronals: F(1, 
347) = 9.58, p = .002, ηp
2 = .03). However, when the names included fricative consonants, a 
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(F(1, 340) = 9.05, p = .003, ηp
2 = .03): voiced (vs. voiceless) consonants in brand names 
increased the expected power in coronal name conditions but not in labial ones (labials: F < 1, 
p = .87; coronals: F(1, 340) = 16.88, p < .001, ηp
2 = .05). 
 
Fig. 3. The results of the influence of the consonants in brand names on the rating of medicine 
effectiveness in Experiment 3.  
4.2.1.2. Perceived duration of medicine activity 
The significant main effects of voiced (vs. voiceless) consonants and coronal (vs. labial) 
consonants on the perceived duration were observed: drugs with voiced (vs. voiceless) brand 
names (F(1, 687) = 9.01, p = .003, ηp
2 = .01; M voiced = 4.03, SD = 1.23; Mvoiceless = 3.80, SD = 
1.12) and drugs with coronal (vs. labial) brand names (F(1, 687) = 6.92, p = .009, ηp
2 = .01; M 
labial = 3.81, SD = 1.10; Mcoronal = 4.03, SD = 1.14) were perceived as having a longer duration. 
Meanwhile, neither the main effect of the manner of articulation, nor any of the interactions, 
were significant (all Fs < 1.68, ps > .20). The three-way interaction between the type of voicing, 
the manner of articulation, and the place of pronunciation was not significant either (F(1, 687) 
= 3.16, p = .076, ηp
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Fig. 4. The results of the influence of the consonants in brand names on the rating of duration 
of medicine activity in Experiment 3.  
4.2.1.3. Price expectation  
The main effect of voiced (vs. voiceless) consonants on the perceived price was 
significant (F(1, 687) = 8.87, p = .003, ηp
2 = .01): Medicines with voiced (vs. voiceless) brand 
names were perceived to be more expensive (M voiced = 4.12, SD = 1.20; Mvoiceless = 3.87, SD = 
1.17). None of the other main effects or interactions were significant (all Fs < 1.55, ps > .21; 
see Figure 5).  
 
Fig. 5. The results of the influence of the consonants in brand names on the rating of medicine 
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4.2.1.4. Potential side effects 
The analysis revealed a significant main effect of the type of voicing (F(1, 687) = 42.94, 
p < .001, ηp
2 = .06): the drugs with voiced (vs. voiceless) brand names were perceived as having 
more potential side effects (Mvoiced = 4.06, SD = 1.11; Mvoiceless = 3.55, SD = 1.06). None of the 
other main effects or two-way interactions was significant (all Fs < 1, ns). In order to examine 
the significant three-way interaction (F(1, 687) = 7.36, p = .007, ηp
2 = .01) more closely, the 
data was split into stop and fricative consonants (see Figure 6). When the names included stop 
consonants, no significant interaction was found between the type of voicing and the place of 
pronunciation (F(1, 347) = 1.71, p = .19, ηp
2 = .01): voiced (vs. voiceless) consonants increased 
the perceived potential side effects regardless of the place of pronunciation (labials: F(1, 347) 
= 14.48, p < .001, ηp
2 = .04; coronals: F(1, 347) = 5.44, p = .02, ηp
2 = .02). However, when the 
names included fricative consonants, a significant interaction was observed between the type 
of voicing and the place of pronunciation (F(1, 340) = 6.51, p = .014, ηp
2 = .02): voiced (vs. 
voiceless) consonants in brand names increased the perceived side effects when they included 
coronal consonants (coronals: F(1, 340) = 23.38, p < .001, ηp
2 = .06), but this was not the case 
when those included labial ones (labials: F(1, 340) = 3.32, p = .07, ηp
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Fig. 6. The results of the influence of the consonants in brand names on the rating of potential 
side effects in Experiment 3.  
 
Table 3. The result summary of the effect of consonants in brand names on medicine 
expectancies in Experiment 3. Note: ns denotes not significant, * denotes p < .05, ** denotes 
p < .01, *** denotes p < .001. 
 
4.2.2. The mediating role of rated EPA for the medicine expectancies 
To examine whether and how the rated EPA for the various brand names mediated the 
effect of voiced (vs. voiceless) brand names on consumers’ expectations regarding the 
medicines, parallel multiple mediation analyses were conducted for the four expectancies 
which were found to be influenced by voiced sounds in the brand names (i.e., medicine 
effectiveness, duration of medicine activity, price, and potential side effects) using Model 4 of 
the PROCESS SPSS macro (Hayes, 2018) with 5000 bootstrap samples (see Figure 7 and Table 
4). 









Voiceless/voiced *** ** ** ***
Fricative/stop ns ns ns ns
Labial/coronal ns ** ns ns
Voiceless/voiced × Fricative/stop ns ns ns ns
Voiceless/voiced × Labial/coronal * ns ns ns
Fricative/stop × Labial/coronal ns ns ns ns
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 The results indicated that the total indirect effect of the voiced (vs. voiceless) brand 
name on the expected medicine effectiveness via the rated EPA was significant (total indirect 
effect = .40, 95% [0.26, 0.55]). The indirect effect via the evaluation showed a negative 
influence of voiced consonants on the rating of the expected medicine effectiveness (indirect 
effect = −.03, 95% [−0.06, 0.00]). Meanwhile, the indirect effect via the potency (indirect effect 
= .35, 95% [0.24, 0.47]) and the activity (indirect effect = .08, 95% [0.03, 0.14]) indicated the 
positive effect of voiced consonants on the expectation of the medicine’s effectiveness. The 
direct effect of voiced consonants on the evaluation of the medicine effectiveness was not 
significant (direct effect = .04, 95% [−0.10, 0.18]). 
4.2.2.2. The mediating effect on the expected duration of medicine activity 
 The total indirect effect of the voiced (vs. voiceless) brand name on the expected type 
of treatment via the rated EPA was significant (total indirect effect = .16, 95% [0.04, 0.27]). 
The indirect effect via the evaluation indicated a negative influence of voiced consonants on 
the expected duration of the medicine’s activity (indirect effect = −.06, 95% [−0.12, −0.02]). 
Meanwhile, the indirect effect via the potency indicated the positive influence of voiced 
consonants on the expected activity duration (indirect effect = .20, 95% [0.12, 0.29]). The 
indirect effect via the activity showed no effect of voiced consonants on the expected activity 
duration (indirect effect = .01, 95% [−0.04, 0.07]). The direct effect of voiced consonants on 
ratings of how long-lasting the drug would be was not significant (direct effect = .08, 95% 
[−0.08, 0.23]). 
4.2.2.3. The mediating effect on price expectation 
 The results revealed a significant total indirect effect of the voiced (vs. voiceless) 
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0.38]). The indirect effect of the evaluation dimension on price perception was not significant 
(indirect effect = .00, 95% [−0.02, 0.03]). Meanwhile, the indirect effect of rated potency 
(indirect effect = .20, 95% [0.12, 0.28]) and rated activity (indirect effect = .08, 95% [0.03, 
0.15]) indicated the positive influence of voiced consonants on the price expectation of the 
medicine. The direct effect of voiced consonants on the expectation was not significant (direct 
effect = −.02, 95% [−0.19, 0.14]). 
4.2.2.4. The mediating effect on expected potential side effects 
 Total indirect effect of the voiced (vs. voiceless) brand name on expected potential side 
effects via the rated EPA was significant (total indirect effect = .31, 95% [0.22, 0.41]). The 
indirect effect of the evaluation dimension showed a positive influence of voiced consonants 
on expected potential side effects (indirect effect = .05, 95% [0.01, 0.11]). Additionally, the 
indirect effect of potency (indirect effect = .19, 95% [0.12, 0.28]) and activity (indirect effect 
= .07, 95% [0.01, 0.13]) also indicated the positive influence of voiced consonants on the 
expected potential side effects. The direct effect of voiced consonants on the ratings of the side 
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Experiment 3 revealed a robust influence of voiced (vs. voiceless) consonants present 
in the brand names on medicine expectancies of the packaged stomach relief drugs. The results 
demonstrated that brand names with voiced (vs. voiceless) consonants increased people’s 
expectations concerning the medicine’s effectiveness, the duration of the medicine’s activity, 
its price, and the occurrence of possible side effects. The results regarding the medicine’s power 
also demonstrated that when the brand names contain stop (vs. fricative) and voiced (vs. 
voiceless) consonants, the expected effectiveness of the drugs is increased, regardless of the 
consonant type (i.e., labial or coronal). 
The results of Experiment 3 further demonstrated the mediating role of perceived 
impressions of brand names on the effect of voiced consonants on the medicine expectancies. 
The perceived potency of the brand names was the most influential mediator amongst Osgood’s 
EPA dimensions (Osgood et al., 1957) and it significantly mediated the effect of voiced 
consonant on the perception of medicine effectiveness, duration of drug activity, price, and 
potential side effects. Rated activity also positively mediated the effect of voiced consonants 
on expectations concerning the medicine’s effectiveness, price, and potential side effects. 
Meanwhile, the rated evaluation positively mediated the effect of voiced consonant on the 
expected potential side effects, however, it negatively mediated the effect on the expected 
effectiveness of the medicine, and the expected duration of the medicine’s activity. The 
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Table 4. Statistical summaries of the influence of voiced consonants in brand names on 
medicine expectations in Experiment 3. Note: Effect estimates are unstandardized regression 
coefficients. 
 
5. General discussion 
5.1. Summary of the study 
With the worldwide growth in OTC drug market, pharmaceutical branding has become 
an increasingly important element in terms of building a competitive edge over competing 
brands and setting the right expectations in the mind of the consumer. The purpose of the 
DV Voiced consonant effect Effect estimate
  Medicine effectiveness Total effect .45   [0.26, 0.63]
Direct effect .04  [-0.10, 0.18]
Indrect effect .40 [0.26 , 0.55]
    via Evaluation -.03 [-0.06, 0.00]
    via Potency .35  [0.24, 0.47]
    via Activity .08  [0.03, 0.14]
  Duration of medicine activity Total effect .23  [0.07, 0.40]
Direct effect .08   [-0.08, 0.23]
Indrect effect .16  [0.04, 0.27]
    via Evaluation -.06 [-0.12, -0.01]
    via Potency .20 [0.12, 0.29]
    via Activity .01 [-0.04, 0.07]
  Expected price Total effect .25  [0.08,  0.43]
Direct effect -.02  [-0.19 , 0.14]
Indrect effect .28 [0.18, 0.38]
    via Evaluation .00  [-0.02, 0.03]
    via Potency .20  [0.12, 0.28]
    via Activity .08  [0.03, 0.15]
  Potential side effects Total effect .51  [0.35, 0.67]
Direct effect .20 [0.05, 0.36]
Indrect effect .31  [0.22, 0.41]
    via Evaluation .05  [0.01, 0.11]
    via Potency .19  [0.12, 0.28]




































































RUNNING HEAD: DRUG NAMES AND THE EXPECTED EFFICACY OF MEDICINES  
present study was to examine whether and how the consonant sounds of brand name influence 
consumer’s expectations for OTC medicines. Sound symbolism literature concerning voiced 
consonants suggests that words containing voiced (vs. voiceless) consonants are perceived to 
be large, heavier, and harsher (e.g., Pathak et al., 2020; Slepian & Galinsky, 2016). Using 
Osgood’s EPA semantic dimensions (Osgood et al., 1957), which enable to capture connotative 
meaning of target stimuli, we predicted that voiced (vs. voiceless) consonants in brand names 
would increase perceived potency and activity while decreasing the perceived evaluation for 
OTC drugs. We also expected that the effect of voiced (vs. voiceless) consonant names on 
medicine expectancies would be mediated by ratings of EPA dimensions. 
The three experiments reported here investigated the effects of voiced consonants in 
brand names on the expected properties of hypothetical new OTC medicines. A robust effect 
of voiced (vs. voiceless) consonants was observed on the expected properties of the various 
medicines. The results of Experiment 1 provided the initial evidence that voiced (vs. voiceless) 
consonants in brand names increased ratings of Osgood’s evaluation, potency, and activity 
dimensions for an anti-allergy medicine. Meanwhile, neither the main effects of stop (vs. 
fricative) consonants, nor the interaction between the type of voicing and the manner of 
articulation, was significant. In Experiment 2, the effect of voiced consonants in brand names 
was further examined by using realistic packaging stimuli for a pain reliever. The results were 
consistent with the findings of Experiment 1 regarding the rated potency and activity 
dimensions. 
Experiment 3 explored the effect of voiced consonant in brand names on the medicinal 
expectancies and the underlying mechanisms using a third category of drug (one that provided 
stomach relief). The results revealed that brand names with voiced (vs. voiceless) consonants 
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its expected price, and also the expected likelihood of potential side effects. Furthermore, we 
found that the effect of voiced consonants on medicinal expectancies is mediated by rated 
potency and activity for the brand names. The rated potency mediated the effect of voicing on 
the expected efficacy of the medicine, how long-lasting it is expected to work, its likely price, 
and the expected potential side effects. Although the overall effects were modest, the rated 
activity of the brand names also mediated the effect of voicing on the perception of medicine 
power, expensiveness, and possible side effects. Meanwhile, we found mixed results for the 
mediating effect of the evaluation dimension. The rated evaluation negatively mediated the 
effect of voicing on medicine effectiveness, duration of medicine activity, but the effect on 
potential side effects was positively mediated by the evaluation dimension. The rated 
evaluation did not significantly mediate the expected price. 
5.2. Implications  
5.2.1. Theoretical implications 
A considerable body of research has shown that the sounds of brand names can elicit a 
variety of product-attribute associations regarding speed, size, strength, shape, sensory 
properties, and gender associations (e.g., Klink, 2000; Lowrey & Shrum, 2007; Spence, 2012, 
2014). However, most of these findings have explored vowels while less attention has been 
paid to the role of consonant sounds in brand name development (Guèvremont & Grohmann, 
2015; Pathak et al., 2020). The present study systematically examined the role of consonants 
in brand names on consumer responses and revealed that voiced (vs. voiceless) consonants 
can significantly alter a consumer’s impressions and expectancies of medicines. More 
importantly, our research further demonstrated the underlying mechanism by which voiced 
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According to Frequency Code Hypothesis, first proposed by Ohala (1984, 1994), low-
frequency sounds convey meanings such as largeness, aggressiveness. As voiced (vs. 
voiceless) consonants are articulated at low frequency, those sounds are thought to elicit the 
above-mentioned associations. Our research confirmed that voiced (vs. voiceless) sounds in 
brand names induce and intensify the semantic impressions of potency and activity. We also 
confirmed that these associations are significant mediators of the effect of voiced sounds on 
the medicine expectancies. Osgood’s potency and activity dimensions may integrate into the 
“dynamism” dimension (Kervyn, Fiske, & Yzerbyt, 2013; Osgood et al., 1957). In this regard, 
it may be said that the dynamism association induced by voiced sounds are the primary cause 
of the effect of sound symbolism on expectations concerning a medicine’s effectiveness. The 
current findings enhance our understanding of the mechanism of voiced sound effects on 
product evaluation and add to a growing body of literature on consonant sound symbolism. 
5.2.2. Managerial implications 
In line with the worldwide growth of the OTC drug market, an increasing number of 
competing brands have been continuously launched to the market in various types of medicines. 
As, in many cases, the active ingredients and the efficacies of branded OTC drugs in a product 
type are more or less the same (e.g., the brands of allergy medicines such as Allegra, Zyrtec, 
Claritin), extrinsic brand cues are of critical importance to build a competitive edge over the 
competing brands and have a great influence on consumers’ decision-making of OTC 
medicines.  
The results reported here clearly suggest that sound symbolism is a useful framework 
that can help the pharmaceutical firms to develop names that can effectively communicate the 
desired properties of a medicine. More specifically, our study shows that it is desirable to use 
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when marketers intend to emphasize medicine effectiveness and/or the duration of medicine 
activity of a target product. It is, though, also important to note that our results suggest the 
associative linkage between the sounds of voiced (vs. voiceless) consonants and the perception 
of higher (vs. lower) potential side effects. Therefore, if marketers want to emphasize a 
medicinal safety as a core benefit of a drug, they may strategically use voiceless consonants in 
the name of the drug for effective brand communication. 
5.3. Limitations and directions for future research 
 One limitation of the current study is that we controlled vowels in brand name stimuli 
and therefore did not examine the possible effect of vowels and the interaction between 
consonants and vowels in brand names on the expected qualities of medicine. As a number of 
published sound symbolism studies have already demonstrated a robust effect of back (vs. 
front) vowels on the perceptions of largeness and heaviness (e.g., Klink, 2000, Lowrey & 
Shrum, 2007), it is expected that the type of vowel in brand names can also influence consumers’ 
expectations concerning the likely properties of medicines. In addition, as vowels and 
consonants have interactive influence the perception of taste such as bitterness (e.g., Motoki et 
al., 2020), the combinations of vowels and consonants in brand names may also affect the 
medicine expectancies through expected taste qualities. Future research could address these 
issues. 
 Another limitation relates to the mixed results of the voiced consonant effect on the 
perceived evaluation. In our study, the evaluation dimension indicates perceived goodness of 
the brand name. Although previous studies suggest that voiced (vs. voiceless) sounds are 
perceived less favorably (e.g., Fjeldsted, 1991), and Experiment 3 of the present study 
confirmed such an effect, we found a more favorable attitude towards voiced (vs. voiceless) 
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Experiment 2. This inconsistency in the pattern of results may well be taken to suggest that the 
perceived goodness of brand names is largely determined by how to embed and combine 
multiple sounds rather than the type of voicing itself in brand names. It would be interesting to 
examine under which conditions voiced consonants in brand names can induce perceived 
goodness. 
The research reported here demonstrates the positive effect of voiced (vs. voiceless) 
consonants in brand name on consumer expectations for medicines such as the effectiveness 
and duration of activity of the medicine. However, the present study also indicates that voiced 
(vs. voiceless) consonants can increase the perception of potential side effects as well. Thus, it 
would be important and intriguing to explore whether it is ever possible to create brand names 
that can convey the meaning of high effectiveness and low potential side effects simultaneously. 
Study 1 of Klink and Wu (2014) shows that although the effect of sound symbolism on 
conveying brand meaning (e.g., largeness) is more robust when the embed is positioned in the 
first (vs. second) syllable in a brand name, the significant sound symbolism effect also exists 
in the second syllable. When we take this into consideration, embedding voiced consonant 
and/or back vowel in the first syllable and voiceless consonant and/or front vowel in the second 
syllable in a brand name might be a solution to create a pharmaceutical brand name that 
connotates effectiveness and gentleness at the same time. 
 
Appendix Table A 








































































Medicine effectiveness 4.20 (1.25) 3.73 (1.13) 3.86 (1.15) 4.15 (1.24) 4.23 (1.23) 4.57 (1.26) 4.38 (1.28) 4.70 (1.25)
Duration of medicine activity 3.76 (1.00) 3.76 (1.35) 3.53 (1.05) 4.06 (1.05) 3.91 (1.10) 4.14 (1.01) 3.98 (1.21) 4.12 (1.15)
Price 3.95 (1.22) 3.80 (1.26) 3.77 (0.97) 3.89 (1.10) 4.02 (1.25) 4.16 (1.27) 4.17 (1.06) 4.14 (1.22)
Potential side effects 3.64 (1.05) 3.39 (1.11) 3.42 (1.10) 3.63 (0.98) 3.93 (1.07) 4.30 (1.29) 4.06 (1.01) 3.98 (1.09)
Voiceless Voiced
Fricative Stop Fricative Stop
Labial CoronalLabial Coronal Labial Coronal Labial Coronal
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